nodes	percent_of_prediction	percent_of_DWPC	metapath
Palonosetron—CYP1A2—Dacarbazine—muscle cancer	0.274	0.404	CbGbCtD
Palonosetron—CYP1A2—Etoposide—muscle cancer	0.134	0.198	CbGbCtD
Palonosetron—CYP3A4—Vincristine—muscle cancer	0.0766	0.113	CbGbCtD
Palonosetron—CYP2D6—Doxorubicin—muscle cancer	0.0753	0.111	CbGbCtD
Palonosetron—CYP3A4—Etoposide—muscle cancer	0.0702	0.104	CbGbCtD
Palonosetron—CYP3A4—Doxorubicin—muscle cancer	0.0479	0.0706	CbGbCtD
Palonosetron—Hypoxia—Methotrexate—muscle cancer	0.00311	0.00966	CcSEcCtD
Palonosetron—Aspartate aminotransferase increased—Dactinomycin—muscle cancer	0.00298	0.00925	CcSEcCtD
Palonosetron—Pain in extremity—Vincristine—muscle cancer	0.00295	0.00918	CcSEcCtD
Palonosetron—Generalised oedema—Doxorubicin—muscle cancer	0.00288	0.00893	CcSEcCtD
Palonosetron—Urinary retention—Vincristine—muscle cancer	0.00281	0.00873	CcSEcCtD
Palonosetron—Cyanosis—Methotrexate—muscle cancer	0.00279	0.00867	CcSEcCtD
Palonosetron—Aspartate aminotransferase increased—Vincristine—muscle cancer	0.00266	0.00826	CcSEcCtD
Palonosetron—Anaphylactoid reaction—Etoposide—muscle cancer	0.00247	0.00768	CcSEcCtD
Palonosetron—Dermatitis atopic—Doxorubicin—muscle cancer	0.00231	0.00718	CcSEcCtD
Palonosetron—Amblyopia—Doxorubicin—muscle cancer	0.00221	0.00688	CcSEcCtD
Palonosetron—Feeling hot—Doxorubicin—muscle cancer	0.00218	0.00677	CcSEcCtD
Palonosetron—Hyperbilirubinaemia—Methotrexate—muscle cancer	0.00217	0.00674	CcSEcCtD
Palonosetron—Glycosuria—Doxorubicin—muscle cancer	0.00211	0.00656	CcSEcCtD
Palonosetron—Hepatic enzyme increased—Methotrexate—muscle cancer	0.00209	0.00648	CcSEcCtD
Palonosetron—Chills—Dactinomycin—muscle cancer	0.00205	0.00638	CcSEcCtD
Palonosetron—Alopecia—Dactinomycin—muscle cancer	0.00202	0.00628	CcSEcCtD
Palonosetron—Urinary tract disorder—Vincristine—muscle cancer	0.00202	0.00627	CcSEcCtD
Palonosetron—Respiratory failure—Methotrexate—muscle cancer	0.00201	0.00625	CcSEcCtD
Palonosetron—Connective tissue disorder—Vincristine—muscle cancer	0.00201	0.00624	CcSEcCtD
Palonosetron—Urethral disorder—Vincristine—muscle cancer	0.002	0.00622	CcSEcCtD
Palonosetron—Erythema—Dactinomycin—muscle cancer	0.00199	0.00618	CcSEcCtD
Palonosetron—Cardiac disorder—Vincristine—muscle cancer	0.0019	0.00589	CcSEcCtD
Palonosetron—Ventricular extrasystoles—Doxorubicin—muscle cancer	0.00189	0.00588	CcSEcCtD
Palonosetron—Hyperbilirubinaemia—Doxorubicin—muscle cancer	0.00188	0.00584	CcSEcCtD
Palonosetron—Hypocalcaemia—Doxorubicin—muscle cancer	0.00187	0.0058	CcSEcCtD
Palonosetron—Angiopathy—Vincristine—muscle cancer	0.00185	0.00576	CcSEcCtD
Palonosetron—Mediastinal disorder—Vincristine—muscle cancer	0.00184	0.00572	CcSEcCtD
Palonosetron—Anaemia—Dactinomycin—muscle cancer	0.00184	0.00572	CcSEcCtD
Palonosetron—Dyskinesia—Doxorubicin—muscle cancer	0.00182	0.00565	CcSEcCtD
Palonosetron—Alopecia—Vincristine—muscle cancer	0.00181	0.00561	CcSEcCtD
Palonosetron—Mental disorder—Vincristine—muscle cancer	0.00179	0.00556	CcSEcCtD
Palonosetron—Hepatobiliary disease—Etoposide—muscle cancer	0.00174	0.00542	CcSEcCtD
Palonosetron—Hiccups—Doxorubicin—muscle cancer	0.00171	0.00531	CcSEcCtD
Palonosetron—Injection site reaction—Doxorubicin—muscle cancer	0.0017	0.00528	CcSEcCtD
Palonosetron—Myalgia—Dactinomycin—muscle cancer	0.0017	0.00527	CcSEcCtD
Palonosetron—Hyperkalaemia—Doxorubicin—muscle cancer	0.00168	0.00522	CcSEcCtD
Palonosetron—Discomfort—Dactinomycin—muscle cancer	0.00168	0.0052	CcSEcCtD
Palonosetron—Influenza like illness—Doxorubicin—muscle cancer	0.00166	0.00516	CcSEcCtD
Palonosetron—Salivary hypersecretion—Doxorubicin—muscle cancer	0.00166	0.00516	CcSEcCtD
Palonosetron—Anaemia—Vincristine—muscle cancer	0.00164	0.00511	CcSEcCtD
Palonosetron—Urinary tract disorder—Etoposide—muscle cancer	0.00164	0.00508	CcSEcCtD
Palonosetron—Fluid retention—Doxorubicin—muscle cancer	0.00162	0.00504	CcSEcCtD
Palonosetron—Urethral disorder—Etoposide—muscle cancer	0.00162	0.00504	CcSEcCtD
Palonosetron—Infection—Dactinomycin—muscle cancer	0.00161	0.00501	CcSEcCtD
Palonosetron—Anorexia—Dactinomycin—muscle cancer	0.00155	0.00481	CcSEcCtD
Palonosetron—Eye disorder—Etoposide—muscle cancer	0.00155	0.00481	CcSEcCtD
Palonosetron—Convulsion—Vincristine—muscle cancer	0.00154	0.00479	CcSEcCtD
Palonosetron—Cardiac disorder—Etoposide—muscle cancer	0.00154	0.00477	CcSEcCtD
Palonosetron—Hypertension—Vincristine—muscle cancer	0.00154	0.00477	CcSEcCtD
Palonosetron—Myalgia—Vincristine—muscle cancer	0.00151	0.0047	CcSEcCtD
Palonosetron—Angiopathy—Etoposide—muscle cancer	0.0015	0.00467	CcSEcCtD
Palonosetron—Immune system disorder—Etoposide—muscle cancer	0.0015	0.00464	CcSEcCtD
Palonosetron—Mediastinal disorder—Etoposide—muscle cancer	0.00149	0.00463	CcSEcCtD
Palonosetron—Chills—Etoposide—muscle cancer	0.00149	0.00461	CcSEcCtD
Palonosetron—Anaphylactoid reaction—Methotrexate—muscle cancer	0.00148	0.0046	CcSEcCtD
Palonosetron—Musculoskeletal discomfort—Dactinomycin—muscle cancer	0.00148	0.0046	CcSEcCtD
Palonosetron—Alopecia—Etoposide—muscle cancer	0.00146	0.00454	CcSEcCtD
Palonosetron—Anaphylactic shock—Vincristine—muscle cancer	0.00145	0.00451	CcSEcCtD
Palonosetron—Infection—Vincristine—muscle cancer	0.00144	0.00448	CcSEcCtD
Palonosetron—Nervous system disorder—Vincristine—muscle cancer	0.00142	0.00442	CcSEcCtD
Palonosetron—Decreased appetite—Dactinomycin—muscle cancer	0.00141	0.00439	CcSEcCtD
Palonosetron—Dysgeusia—Etoposide—muscle cancer	0.00141	0.00438	CcSEcCtD
Palonosetron—Fatigue—Dactinomycin—muscle cancer	0.0014	0.00435	CcSEcCtD
Palonosetron—Pain—Dactinomycin—muscle cancer	0.00139	0.00432	CcSEcCtD
Palonosetron—Anorexia—Vincristine—muscle cancer	0.00138	0.0043	CcSEcCtD
Palonosetron—Hypotension—Vincristine—muscle cancer	0.00136	0.00421	CcSEcCtD
Palonosetron—Anaemia—Etoposide—muscle cancer	0.00133	0.00414	CcSEcCtD
Palonosetron—Gastrointestinal pain—Dactinomycin—muscle cancer	0.00133	0.00413	CcSEcCtD
Palonosetron—Hot flush—Doxorubicin—muscle cancer	0.00133	0.00412	CcSEcCtD
Palonosetron—Musculoskeletal discomfort—Vincristine—muscle cancer	0.00132	0.00411	CcSEcCtD
Palonosetron—Menopausal symptoms—Doxorubicin—muscle cancer	0.00132	0.00409	CcSEcCtD
Palonosetron—Insomnia—Vincristine—muscle cancer	0.00131	0.00408	CcSEcCtD
Palonosetron—Paraesthesia—Vincristine—muscle cancer	0.0013	0.00405	CcSEcCtD
Palonosetron—Abdominal pain—Dactinomycin—muscle cancer	0.00128	0.00399	CcSEcCtD
Palonosetron—Body temperature increased—Dactinomycin—muscle cancer	0.00128	0.00399	CcSEcCtD
Palonosetron—Anaphylactoid reaction—Doxorubicin—muscle cancer	0.00128	0.00398	CcSEcCtD
Palonosetron—Decreased appetite—Vincristine—muscle cancer	0.00126	0.00392	CcSEcCtD
Palonosetron—Gastrointestinal disorder—Vincristine—muscle cancer	0.00125	0.00389	CcSEcCtD
Palonosetron—Fatigue—Vincristine—muscle cancer	0.00125	0.00389	CcSEcCtD
Palonosetron—Convulsion—Etoposide—muscle cancer	0.00125	0.00388	CcSEcCtD
Palonosetron—Hypertension—Etoposide—muscle cancer	0.00124	0.00386	CcSEcCtD
Palonosetron—Pain—Vincristine—muscle cancer	0.00124	0.00386	CcSEcCtD
Palonosetron—Constipation—Vincristine—muscle cancer	0.00124	0.00386	CcSEcCtD
Palonosetron—Pain in extremity—Doxorubicin—muscle cancer	0.00124	0.00386	CcSEcCtD
Palonosetron—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	0.00122	0.00378	CcSEcCtD
Palonosetron—Discomfort—Etoposide—muscle cancer	0.00121	0.00377	CcSEcCtD
Palonosetron—Hypersensitivity—Dactinomycin—muscle cancer	0.0012	0.00372	CcSEcCtD
Palonosetron—Gastrointestinal pain—Vincristine—muscle cancer	0.00119	0.00369	CcSEcCtD
Palonosetron—Anaphylactic shock—Etoposide—muscle cancer	0.00118	0.00365	CcSEcCtD
Palonosetron—Infection—Etoposide—muscle cancer	0.00117	0.00363	CcSEcCtD
Palonosetron—Asthenia—Dactinomycin—muscle cancer	0.00117	0.00362	CcSEcCtD
Palonosetron—Tachycardia—Etoposide—muscle cancer	0.00115	0.00357	CcSEcCtD
Palonosetron—Abdominal pain—Vincristine—muscle cancer	0.00115	0.00357	CcSEcCtD
Palonosetron—Body temperature increased—Vincristine—muscle cancer	0.00115	0.00357	CcSEcCtD
Palonosetron—Skin disorder—Etoposide—muscle cancer	0.00114	0.00355	CcSEcCtD
Palonosetron—Abdominal pain upper—Doxorubicin—muscle cancer	0.00113	0.00352	CcSEcCtD
Palonosetron—Hypokalaemia—Doxorubicin—muscle cancer	0.00113	0.00351	CcSEcCtD
Palonosetron—Anorexia—Etoposide—muscle cancer	0.00112	0.00348	CcSEcCtD
Palonosetron—Aspartate aminotransferase increased—Doxorubicin—muscle cancer	0.00112	0.00347	CcSEcCtD
Palonosetron—Diarrhoea—Dactinomycin—muscle cancer	0.00111	0.00345	CcSEcCtD
Palonosetron—Hypotension—Etoposide—muscle cancer	0.0011	0.00341	CcSEcCtD
Palonosetron—Gastritis—Doxorubicin—muscle cancer	0.0011	0.00341	CcSEcCtD
Palonosetron—Abdominal distension—Doxorubicin—muscle cancer	0.00108	0.00335	CcSEcCtD
Palonosetron—Hypersensitivity—Vincristine—muscle cancer	0.00107	0.00332	CcSEcCtD
Palonosetron—Paraesthesia—Etoposide—muscle cancer	0.00106	0.00328	CcSEcCtD
Palonosetron—Dyspnoea—Etoposide—muscle cancer	0.00105	0.00326	CcSEcCtD
Palonosetron—Somnolence—Etoposide—muscle cancer	0.00105	0.00325	CcSEcCtD
Palonosetron—Hepatobiliary disease—Methotrexate—muscle cancer	0.00104	0.00324	CcSEcCtD
Palonosetron—Epistaxis—Methotrexate—muscle cancer	0.00104	0.00324	CcSEcCtD
Palonosetron—Asthenia—Vincristine—muscle cancer	0.00104	0.00324	CcSEcCtD
Palonosetron—Vomiting—Dactinomycin—muscle cancer	0.00103	0.00321	CcSEcCtD
Palonosetron—Rash—Dactinomycin—muscle cancer	0.00102	0.00318	CcSEcCtD
Palonosetron—Decreased appetite—Etoposide—muscle cancer	0.00102	0.00318	CcSEcCtD
Palonosetron—Gastrointestinal disorder—Etoposide—muscle cancer	0.00102	0.00315	CcSEcCtD
Palonosetron—Fatigue—Etoposide—muscle cancer	0.00101	0.00315	CcSEcCtD
Palonosetron—Constipation—Etoposide—muscle cancer	0.00101	0.00312	CcSEcCtD
Palonosetron—Pain—Etoposide—muscle cancer	0.00101	0.00312	CcSEcCtD
Palonosetron—Diarrhoea—Vincristine—muscle cancer	0.000994	0.00309	CcSEcCtD
Palonosetron—Urinary tract disorder—Methotrexate—muscle cancer	0.000979	0.00304	CcSEcCtD
Palonosetron—Urethral disorder—Methotrexate—muscle cancer	0.000972	0.00302	CcSEcCtD
Palonosetron—Hyperglycaemia—Doxorubicin—muscle cancer	0.000968	0.00301	CcSEcCtD
Palonosetron—Nausea—Dactinomycin—muscle cancer	0.000965	0.003	CcSEcCtD
Palonosetron—Gastrointestinal pain—Etoposide—muscle cancer	0.000962	0.00299	CcSEcCtD
Palonosetron—Dizziness—Vincristine—muscle cancer	0.00096	0.00298	CcSEcCtD
Palonosetron—Abdominal pain—Etoposide—muscle cancer	0.00093	0.00289	CcSEcCtD
Palonosetron—Body temperature increased—Etoposide—muscle cancer	0.00093	0.00289	CcSEcCtD
Palonosetron—Eye disorder—Methotrexate—muscle cancer	0.000927	0.00288	CcSEcCtD
Palonosetron—Tinnitus—Methotrexate—muscle cancer	0.000925	0.00287	CcSEcCtD
Palonosetron—Vomiting—Vincristine—muscle cancer	0.000923	0.00287	CcSEcCtD
Palonosetron—Cardiac disorder—Methotrexate—muscle cancer	0.00092	0.00286	CcSEcCtD
Palonosetron—Rash—Vincristine—muscle cancer	0.000916	0.00284	CcSEcCtD
Palonosetron—Dermatitis—Vincristine—muscle cancer	0.000915	0.00284	CcSEcCtD
Palonosetron—Headache—Vincristine—muscle cancer	0.00091	0.00283	CcSEcCtD
Palonosetron—Hepatobiliary disease—Doxorubicin—muscle cancer	0.000905	0.00281	CcSEcCtD
Palonosetron—Epistaxis—Doxorubicin—muscle cancer	0.000902	0.0028	CcSEcCtD
Palonosetron—Angiopathy—Methotrexate—muscle cancer	0.0009	0.00279	CcSEcCtD
Palonosetron—Sinusitis—Doxorubicin—muscle cancer	0.000898	0.00279	CcSEcCtD
Palonosetron—Immune system disorder—Methotrexate—muscle cancer	0.000896	0.00278	CcSEcCtD
Palonosetron—Mediastinal disorder—Methotrexate—muscle cancer	0.000894	0.00278	CcSEcCtD
Palonosetron—Chills—Methotrexate—muscle cancer	0.00089	0.00276	CcSEcCtD
Palonosetron—Alopecia—Methotrexate—muscle cancer	0.000876	0.00272	CcSEcCtD
Palonosetron—Bradycardia—Doxorubicin—muscle cancer	0.000874	0.00272	CcSEcCtD
Palonosetron—Mental disorder—Methotrexate—muscle cancer	0.000869	0.0027	CcSEcCtD
Palonosetron—Hypersensitivity—Etoposide—muscle cancer	0.000867	0.00269	CcSEcCtD
Palonosetron—Erythema—Methotrexate—muscle cancer	0.000863	0.00268	CcSEcCtD
Palonosetron—Malnutrition—Methotrexate—muscle cancer	0.000863	0.00268	CcSEcCtD
Palonosetron—Nausea—Vincristine—muscle cancer	0.000863	0.00268	CcSEcCtD
Palonosetron—Urinary tract disorder—Doxorubicin—muscle cancer	0.000848	0.00263	CcSEcCtD
Palonosetron—Dysgeusia—Methotrexate—muscle cancer	0.000845	0.00263	CcSEcCtD
Palonosetron—Asthenia—Etoposide—muscle cancer	0.000844	0.00262	CcSEcCtD
Palonosetron—Connective tissue disorder—Doxorubicin—muscle cancer	0.000844	0.00262	CcSEcCtD
Palonosetron—Urethral disorder—Doxorubicin—muscle cancer	0.000842	0.00261	CcSEcCtD
Palonosetron—Pruritus—Etoposide—muscle cancer	0.000832	0.00258	CcSEcCtD
Palonosetron—Diarrhoea—Etoposide—muscle cancer	0.000805	0.0025	CcSEcCtD
Palonosetron—Eye disorder—Doxorubicin—muscle cancer	0.000803	0.00249	CcSEcCtD
Palonosetron—Tinnitus—Doxorubicin—muscle cancer	0.000801	0.00249	CcSEcCtD
Palonosetron—Anaemia—Methotrexate—muscle cancer	0.000798	0.00248	CcSEcCtD
Palonosetron—Cardiac disorder—Doxorubicin—muscle cancer	0.000797	0.00248	CcSEcCtD
Palonosetron—Angiopathy—Doxorubicin—muscle cancer	0.000779	0.00242	CcSEcCtD
Palonosetron—Dizziness—Etoposide—muscle cancer	0.000778	0.00242	CcSEcCtD
Palonosetron—Immune system disorder—Doxorubicin—muscle cancer	0.000776	0.00241	CcSEcCtD
Palonosetron—Mediastinal disorder—Doxorubicin—muscle cancer	0.000774	0.0024	CcSEcCtD
Palonosetron—Chills—Doxorubicin—muscle cancer	0.000771	0.00239	CcSEcCtD
Palonosetron—Arrhythmia—Doxorubicin—muscle cancer	0.000767	0.00238	CcSEcCtD
Palonosetron—Alopecia—Doxorubicin—muscle cancer	0.000759	0.00236	CcSEcCtD
Palonosetron—Mental disorder—Doxorubicin—muscle cancer	0.000752	0.00234	CcSEcCtD
Palonosetron—Convulsion—Methotrexate—muscle cancer	0.000748	0.00232	CcSEcCtD
Palonosetron—Vomiting—Etoposide—muscle cancer	0.000748	0.00232	CcSEcCtD
Palonosetron—Malnutrition—Doxorubicin—muscle cancer	0.000748	0.00232	CcSEcCtD
Palonosetron—Erythema—Doxorubicin—muscle cancer	0.000748	0.00232	CcSEcCtD
Palonosetron—Rash—Etoposide—muscle cancer	0.000742	0.0023	CcSEcCtD
Palonosetron—Dermatitis—Etoposide—muscle cancer	0.000741	0.0023	CcSEcCtD
Palonosetron—Headache—Etoposide—muscle cancer	0.000737	0.00229	CcSEcCtD
Palonosetron—Flatulence—Doxorubicin—muscle cancer	0.000737	0.00229	CcSEcCtD
Palonosetron—Arthralgia—Methotrexate—muscle cancer	0.000735	0.00228	CcSEcCtD
Palonosetron—Myalgia—Methotrexate—muscle cancer	0.000735	0.00228	CcSEcCtD
Palonosetron—Dysgeusia—Doxorubicin—muscle cancer	0.000732	0.00227	CcSEcCtD
Palonosetron—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	0.00073	0.00227	CcSEcCtD
Palonosetron—Discomfort—Methotrexate—muscle cancer	0.000726	0.00226	CcSEcCtD
Palonosetron—Anaphylactic shock—Methotrexate—muscle cancer	0.000705	0.00219	CcSEcCtD
Palonosetron—Infection—Methotrexate—muscle cancer	0.0007	0.00217	CcSEcCtD
Palonosetron—Nausea—Etoposide—muscle cancer	0.000699	0.00217	CcSEcCtD
Palonosetron—Nervous system disorder—Methotrexate—muscle cancer	0.000691	0.00215	CcSEcCtD
Palonosetron—Anaemia—Doxorubicin—muscle cancer	0.000691	0.00215	CcSEcCtD
Palonosetron—Skin disorder—Methotrexate—muscle cancer	0.000684	0.00213	CcSEcCtD
Palonosetron—Anorexia—Methotrexate—muscle cancer	0.000672	0.00209	CcSEcCtD
Palonosetron—Hypotension—Methotrexate—muscle cancer	0.000658	0.00204	CcSEcCtD
Palonosetron—Convulsion—Doxorubicin—muscle cancer	0.000648	0.00201	CcSEcCtD
Palonosetron—Hypertension—Doxorubicin—muscle cancer	0.000645	0.002	CcSEcCtD
Palonosetron—Musculoskeletal discomfort—Methotrexate—muscle cancer	0.000642	0.00199	CcSEcCtD
Palonosetron—Insomnia—Methotrexate—muscle cancer	0.000637	0.00198	CcSEcCtD
Palonosetron—Arthralgia—Doxorubicin—muscle cancer	0.000636	0.00198	CcSEcCtD
Palonosetron—Myalgia—Doxorubicin—muscle cancer	0.000636	0.00198	CcSEcCtD
Palonosetron—Anxiety—Doxorubicin—muscle cancer	0.000634	0.00197	CcSEcCtD
Palonosetron—Paraesthesia—Methotrexate—muscle cancer	0.000633	0.00196	CcSEcCtD
Palonosetron—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	0.000632	0.00196	CcSEcCtD
Palonosetron—Discomfort—Doxorubicin—muscle cancer	0.000629	0.00195	CcSEcCtD
Palonosetron—Dyspnoea—Methotrexate—muscle cancer	0.000628	0.00195	CcSEcCtD
Palonosetron—Somnolence—Methotrexate—muscle cancer	0.000626	0.00195	CcSEcCtD
Palonosetron—Dry mouth—Doxorubicin—muscle cancer	0.000622	0.00193	CcSEcCtD
Palonosetron—Dyspepsia—Methotrexate—muscle cancer	0.00062	0.00193	CcSEcCtD
Palonosetron—Decreased appetite—Methotrexate—muscle cancer	0.000613	0.0019	CcSEcCtD
Palonosetron—Anaphylactic shock—Doxorubicin—muscle cancer	0.00061	0.00189	CcSEcCtD
Palonosetron—Gastrointestinal disorder—Methotrexate—muscle cancer	0.000608	0.00189	CcSEcCtD
Palonosetron—Fatigue—Methotrexate—muscle cancer	0.000607	0.00189	CcSEcCtD
Palonosetron—Infection—Doxorubicin—muscle cancer	0.000606	0.00188	CcSEcCtD
Palonosetron—Pain—Methotrexate—muscle cancer	0.000603	0.00187	CcSEcCtD
Palonosetron—Shock—Doxorubicin—muscle cancer	0.0006	0.00186	CcSEcCtD
Palonosetron—Nervous system disorder—Doxorubicin—muscle cancer	0.000598	0.00186	CcSEcCtD
Palonosetron—Tachycardia—Doxorubicin—muscle cancer	0.000595	0.00185	CcSEcCtD
Palonosetron—Skin disorder—Doxorubicin—muscle cancer	0.000593	0.00184	CcSEcCtD
Palonosetron—Anorexia—Doxorubicin—muscle cancer	0.000582	0.00181	CcSEcCtD
Palonosetron—Gastrointestinal pain—Methotrexate—muscle cancer	0.000576	0.00179	CcSEcCtD
Palonosetron—Hypotension—Doxorubicin—muscle cancer	0.00057	0.00177	CcSEcCtD
Palonosetron—Body temperature increased—Methotrexate—muscle cancer	0.000557	0.00173	CcSEcCtD
Palonosetron—Abdominal pain—Methotrexate—muscle cancer	0.000557	0.00173	CcSEcCtD
Palonosetron—Musculoskeletal discomfort—Doxorubicin—muscle cancer	0.000556	0.00173	CcSEcCtD
Palonosetron—Insomnia—Doxorubicin—muscle cancer	0.000552	0.00171	CcSEcCtD
Palonosetron—Paraesthesia—Doxorubicin—muscle cancer	0.000548	0.0017	CcSEcCtD
Palonosetron—Dyspnoea—Doxorubicin—muscle cancer	0.000544	0.00169	CcSEcCtD
Palonosetron—Somnolence—Doxorubicin—muscle cancer	0.000542	0.00168	CcSEcCtD
Palonosetron—Dyspepsia—Doxorubicin—muscle cancer	0.000537	0.00167	CcSEcCtD
Palonosetron—Decreased appetite—Doxorubicin—muscle cancer	0.00053	0.00165	CcSEcCtD
Palonosetron—Gastrointestinal disorder—Doxorubicin—muscle cancer	0.000527	0.00164	CcSEcCtD
Palonosetron—Fatigue—Doxorubicin—muscle cancer	0.000526	0.00163	CcSEcCtD
Palonosetron—Pain—Doxorubicin—muscle cancer	0.000522	0.00162	CcSEcCtD
Palonosetron—Constipation—Doxorubicin—muscle cancer	0.000522	0.00162	CcSEcCtD
Palonosetron—Hypersensitivity—Methotrexate—muscle cancer	0.000519	0.00161	CcSEcCtD
Palonosetron—Asthenia—Methotrexate—muscle cancer	0.000506	0.00157	CcSEcCtD
Palonosetron—Gastrointestinal pain—Doxorubicin—muscle cancer	0.000499	0.00155	CcSEcCtD
Palonosetron—Pruritus—Methotrexate—muscle cancer	0.000499	0.00155	CcSEcCtD
Palonosetron—Body temperature increased—Doxorubicin—muscle cancer	0.000482	0.0015	CcSEcCtD
Palonosetron—Abdominal pain—Doxorubicin—muscle cancer	0.000482	0.0015	CcSEcCtD
Palonosetron—Diarrhoea—Methotrexate—muscle cancer	0.000482	0.0015	CcSEcCtD
Palonosetron—Dizziness—Methotrexate—muscle cancer	0.000466	0.00145	CcSEcCtD
Palonosetron—Hypersensitivity—Doxorubicin—muscle cancer	0.00045	0.0014	CcSEcCtD
Palonosetron—Vomiting—Methotrexate—muscle cancer	0.000448	0.00139	CcSEcCtD
Palonosetron—Rash—Methotrexate—muscle cancer	0.000444	0.00138	CcSEcCtD
Palonosetron—Dermatitis—Methotrexate—muscle cancer	0.000444	0.00138	CcSEcCtD
Palonosetron—Headache—Methotrexate—muscle cancer	0.000441	0.00137	CcSEcCtD
Palonosetron—Asthenia—Doxorubicin—muscle cancer	0.000438	0.00136	CcSEcCtD
Palonosetron—Pruritus—Doxorubicin—muscle cancer	0.000432	0.00134	CcSEcCtD
Palonosetron—Nausea—Methotrexate—muscle cancer	0.000419	0.0013	CcSEcCtD
Palonosetron—Diarrhoea—Doxorubicin—muscle cancer	0.000417	0.0013	CcSEcCtD
Palonosetron—Dizziness—Doxorubicin—muscle cancer	0.000403	0.00125	CcSEcCtD
Palonosetron—Vomiting—Doxorubicin—muscle cancer	0.000388	0.0012	CcSEcCtD
Palonosetron—Rash—Doxorubicin—muscle cancer	0.000385	0.00119	CcSEcCtD
Palonosetron—Dermatitis—Doxorubicin—muscle cancer	0.000384	0.00119	CcSEcCtD
Palonosetron—Headache—Doxorubicin—muscle cancer	0.000382	0.00119	CcSEcCtD
Palonosetron—Nausea—Doxorubicin—muscle cancer	0.000362	0.00113	CcSEcCtD
